Wall Street brokerages expect Sierra Oncology Inc (NASDAQ:SRRA) to announce earnings per share of ($0.22) for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Sierra Oncology’s earnings, with the highest EPS estimate coming in at ($0.21) and the lowest estimate coming in at ($0.23). Sierra Oncology posted earnings of ($0.21) per share during the same quarter last year, which suggests a negative year-over-year growth rate of 4.8%. The firm is scheduled to issue its next earnings report on Thursday, November 14th.

On average, analysts expect that Sierra Oncology will report full-year earnings of ($0.80) per share for the current fiscal year, with EPS estimates ranging from ($0.83) to ($0.76). For the next financial year, analysts anticipate that the business will post earnings of ($0.84) per share, with EPS estimates ranging from ($0.91) to ($0.75). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that follow Sierra Oncology.

Sierra Oncology (NASDAQ:SRRA) last released its earnings results on Thursday, August 8th. The biotechnology company reported ($0.20) earnings per share for the quarter, meeting the consensus estimate of ($0.20).

Several equities analysts have weighed in on the company. ValuEngine raised Sierra Oncology from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Zacks Investment Research lowered Sierra Oncology from a “buy” rating to a “hold” rating in a research note on Friday.

NASDAQ:SRRA remained flat at $$0.43 during mid-day trading on Monday. The company’s stock had a trading volume of 184,600 shares, compared to its average volume of 406,235. Sierra Oncology has a 1 year low of $0.40 and a 1 year high of $2.07. The company has a fifty day moving average price of $0.53 and a two-hundred day moving average price of $1.20. The company has a current ratio of 9.24, a quick ratio of 13.07 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $32.85 million, a price-to-earnings ratio of -0.57 and a beta of 1.24.

A number of hedge funds have recently bought and sold shares of the business. Brookstone Capital Management bought a new position in Sierra Oncology in the first quarter valued at approximately $28,000. Virtu Financial LLC bought a new position in Sierra Oncology in the first quarter valued at approximately $32,000. JPMorgan Chase & Co. grew its stake in Sierra Oncology by 981.2% in the second quarter. JPMorgan Chase & Co. now owns 43,703 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 39,661 shares in the last quarter. Acadian Asset Management LLC grew its stake in Sierra Oncology by 19.5% in the first quarter. Acadian Asset Management LLC now owns 486,493 shares of the biotechnology company’s stock valued at $831,000 after purchasing an additional 79,388 shares in the last quarter. Finally, Renaissance Technologies LLC grew its stake in Sierra Oncology by 22.0% in the second quarter. Renaissance Technologies LLC now owns 2,312,634 shares of the biotechnology company’s stock valued at $1,295,000 after purchasing an additional 417,300 shares in the last quarter. Hedge funds and other institutional investors own 62.61% of the company’s stock.

About Sierra Oncology

Sierra Oncology, Inc, a clinical stage drug development company, is advancing targeted therapeutics for the treatment of patients with unmet medical needs in hematology and oncology. Its lead drug candidate, momelotinib, is a selective and orally-bioavailable JAK1, JAK2, and ACVR1 inhibitor that has been investigated in two completed Phase 3 trials for the treatment of myelofibrosis and has demonstrated a differentiated therapeutic profile encompassing anemia-related benefits, as well as achieving substantive splenic volume reduction and constitutional symptom control.

Recommended Story: Do equity income investments outperform growth and income investments?

Get a free copy of the Zacks research report on Sierra Oncology (SRRA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Sierra Oncology (NASDAQ:SRRA)

Receive News & Ratings for Sierra Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sierra Oncology and related companies with MarketBeat.com's FREE daily email newsletter.